Development of a broad-spectrum nasal live attenuated influenza vaccine based on mosaic antigen design against influenza B viruses.

ABSTRACT: ABSTRACTInfluenza B virus (IBV) causes significant seasonal disease burden, and frequent antigenic drift limits the effectiveness of conventional vaccines. To address this, we designed mosaic haemagglutinin (HA) and neuraminidase (NA) antigens to maximize T-cell epitope coverage and incorporated them into a nasal live attenuated influenza vaccine (LAIV) platform. Using B/Victoria lineage sequences (2009-2021), mosaic HA/NA candidates were generated via an iterative genetic algorithm. BALB/c mice were randomized into PBS, conventional inactivated influenza vaccine (IIV), conventional LAIV, and mosaic-LAIV (MoBV) groups, and immunized intranasally on days 0 and 14. Immune responses were evaluated by haemagglutination inhibition (HAI), microneutralization (MN), neuraminidase inhibition

SUBMITTER: Han X 

PROVIDER: S-EPMC12573537 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature